The US Food and Drug Administration (FDA) has issued a new raft of warning letters to firms marketing glucagonâlike peptideâ1 (GLPâ1) receptor agonists and related compounds without required regulatory authorization.
On April 7, 2026, the FDA cited seven companies for distributing GLPâ1 products, dual GLPâ1/glucoseâdependent insulinotropic polypeptide (GIP) products,